Evidence map›Paper›PMID 41377965›Full record

ArticleResearch square2025

Species-specific AAVR dominates species-tropism of adeno-associated virus (AAV) vectors.

Mark Kay, Yuqian Jiang, Yiming Liu, Yuqing Jing, Feijie Zhang, Angela Lin

Abstract readPreprint
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mark KayStanford University.ORCID 0000-0002-2799-2615
Yuqian JiangStanford University.
Yiming LiuStanford University.
Yuqing JingStanford University.
Feijie Zhangstanford.
Angela LinStanford University.

Funding

HEPATIC GENE TRANSFER FOR TREATMENT OF HEMOPHILIAS A &BR01HL064274 · NHLBI · STANFORD UNIVERSITY · PI Mark A Kay · 2000 to 2026
$13.6M
Selection of New rAAV Vectors Using Replicating Viral Capsids LibrariesR01AI116698 · NIAID · STANFORD UNIVERSITY · PI Mark A Kay · 2015 to 2026
$8.0M
NHLBI NIH HHS R01 HL064274NIAID NIH HHS R01 AI116698
6 · The paper itself

Abstract

The variation in AAV vector mediated transduction between species makes it difficult to predict and translate from preclinical animal studies to clinical trials. We previously demonstrated that a 265G insertion (AAV-AM) into the AAV-LK03 primate selective capsid allows robust transduction between species. Here we demonstrate that the capsid species specificity cannot be complemented in trans and hence the transduction properties are cis mediated. We found that the 265G is in a surface-exposed region of AAV virion, facilitating its accessibility for binding to the universal AAVR receptor. We further demonstrated that human AAVR (hAAVR) supplementation rescued the low murine transduction of AAV-LK03 in vitro and in vivo. Sequence swap experiments demonstrated the four amino acid variation of mouse vs human PKD2 domain was important for the varied species tropism of AAV-LK03, with I426V having the greatest effect. Our findings imply that transduction efficiencies between various AAV capsids are substantially influenced by sequence variation in the AAVR protein observed between species. This may facilitate better approaches for translating preclinical to clinical application of AAV-based gene therapeutics.

Indexed as

AAV-LK03AAVRAdeno Associated Virus (AAV)gene therapyspecies tropism

Identifiers

PMID41377965
PMCPMC12687847

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.